Clinical Trial Update: A Study to Assess the Long-term Efficacy (24 Weeks) of MPC-4326 in Combination With a 2-3 Drug OBR Relative to the Efficacy of a 3-4 Drug ARV Regimen in Treatment Experienced HIV-1 Infected Subjects Who Are Failing Current Antiretroviral Therapy [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the long-term efficacy of MPC-4326 in combination with an optimized background regimen versus a 3-4 drug antiretroviral regimen in trea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• MPC-4326

Snippet

Sponsor: Myrexis Inc. | Conditions: HIV Infections | Phase 2 | Status: TERMINATED